No Data
No Data
Q32 Bio (QTTB) Receives a Rating Update From a Top Analyst
Q32 Bio Completes Enrollment in Mid-Stage Atopic Dermatitis Trial
Q32 Bio (QTTB) said Tuesday it has completed enrollment in the SIGNAL-AD Phase 2 trial of bempikibart for the treatment of persistent, moderate-to-severe atopic dermatitis in adult patients.The
Q32 Bio Advances in Atopic Dermatitis Treatment Trial
Express News | Q32 Bio Inc - Bempikibart Topline Results on Track for Q4'24
Express News | Q32 Bio Announces Completion of Enrollment in the Signal-Ad Phase 2 Clinical Trial of Bempikibart for Atopic Dermatitis
Q32 Bio Announces Completion of Enrollment in the SIGNAL-AD Phase 2 Clinical Trial of Bempikibart for Atopic Dermatitis
A total of 121 patients were enrolled, including 15 patients in Part A. Total enrollment exceeded the initial target of approximately 100 patients due to Part B patient enrollment demand.
No Data